FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973442967> ?p ?o ?g. }

• W1973442967 endingPage "e607" @default.
• W1973442967 startingPage "e601" @default.
• W1973442967 abstract "OBJECTIVE. In utero exposure to drugs of abuse can lead to neonatal abstinence syndrome, a condition that is associated with prolonged hospitalization. Buprenorphine is a partial μ-opioid agonist used for treatment of adult detoxification and maintenance but has never been administered to neonates with opioid abstinence syndrome. The primary objective of this study was to demonstrate the feasibility and, to the extent possible in this size of study, the safety of sublingual buprenorphine in the treatment of neonatal abstinence syndrome. Secondary goals were to evaluate efficacy relative to standard therapy and to characterize buprenorphine pharmacokinetics when sublingually administered. METHODS. We conducted a randomized, open-label, active-control study of sublingual buprenorphine for the treatment of opiate withdrawal. Thirteen term infants were allocated to receive sublingual buprenorphine 13.2 to 39.0 μg/kg per day administered in 3 divided doses and 13 to receive standard-of-care oral neonatal opium solution. Dose decisions were made by using a modified Finnegan scoring system. RESULTS. Sublingual buprenorphine was largely effective in controlling neonatal abstinence syndrome. Greater than 98% of plasma concentrations ranged from undetectable to ∼0.60 ng/mL, which is less than needed to control abstinence symptoms in adults. The ratio of buprenorphine to norbuprenorphine was larger than that seen in adults, suggesting a relative impairment of N-dealkylation. Three infants who received buprenorphine and 1 infant who received standard of care reached protocol-specified maximum doses and required adjuvant therapy with phenobarbital. The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group. The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group. Treatment with buprenorphine was well tolerated. CONCLUSIONS. Buprenorphine administered via the sublingual route is feasible and apparently safe and may represent a novel treatment for neonatal abstinence syndrome." @default.
• W1973442967 created "2016-06-24" @default.
• W1973442967 creator A5023309852 @default.
• W1973442967 creator A5024592614 @default.
• W1973442967 creator A5027885433 @default.
• W1973442967 creator A5031442075 @default.
• W1973442967 creator A5041269947 @default.
• W1973442967 creator A5042584177 @default.
• W1973442967 creator A5060607144 @default.
• W1973442967 creator A5065674606 @default.
• W1973442967 creator A5087339700 @default.
• W1973442967 date "2008-09-01" @default.
• W1973442967 modified "2023-09-25" @default.
• W1973442967 title "Sublingual Buprenorphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Trial" @default.
• W1973442967 cites W157516614 @default.
• W1973442967 cites W1971962043 @default.
• W1973442967 cites W1978026091 @default.
• W1973442967 cites W1978986104 @default.
• W1973442967 cites W1979600943 @default.
• W1973442967 cites W1984956006 @default.
• W1973442967 cites W1986797986 @default.
• W1973442967 cites W1987442087 @default.
• W1973442967 cites W1992389336 @default.
• W1973442967 cites W2000785257 @default.
• W1973442967 cites W2003410717 @default.
• W1973442967 cites W2003691148 @default.
• W1973442967 cites W2032694883 @default.
• W1973442967 cites W2033312182 @default.
• W1973442967 cites W2033991790 @default.
• W1973442967 cites W2039011163 @default.
• W1973442967 cites W2039946626 @default.
• W1973442967 cites W2057416007 @default.
• W1973442967 cites W2062768605 @default.
• W1973442967 cites W2068126738 @default.
• W1973442967 cites W2083145679 @default.
• W1973442967 cites W2088320391 @default.
• W1973442967 cites W2089180090 @default.
• W1973442967 cites W2089259236 @default.
• W1973442967 cites W2098684993 @default.
• W1973442967 cites W2130312549 @default.
• W1973442967 cites W2141703848 @default.
• W1973442967 cites W2153902825 @default.
• W1973442967 cites W2166820300 @default.
• W1973442967 cites W2337828484 @default.
• W1973442967 cites W4205138644 @default.
• W1973442967 cites W4205681612 @default.
• W1973442967 cites W4234319637 @default.
• W1973442967 cites W4235866329 @default.
• W1973442967 cites W93013761 @default.
• W1973442967 doi "https://doi.org/10.1542/peds.2008-0571" @default.
• W1973442967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2574639" @default.
• W1973442967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18694901" @default.
• W1973442967 hasPublicationYear "2008" @default.
• W1973442967 type Work @default.
• W1973442967 sameAs 1973442967 @default.
• W1973442967 citedByCount "97" @default.
• W1973442967 countsByYear W19734429672012 @default.
• W1973442967 countsByYear W19734429672013 @default.
• W1973442967 countsByYear W19734429672014 @default.
• W1973442967 countsByYear W19734429672015 @default.
• W1973442967 countsByYear W19734429672016 @default.
• W1973442967 countsByYear W19734429672017 @default.
• W1973442967 countsByYear W19734429672018 @default.
• W1973442967 countsByYear W19734429672019 @default.
• W1973442967 countsByYear W19734429672020 @default.
• W1973442967 countsByYear W19734429672021 @default.
• W1973442967 countsByYear W19734429672023 @default.
• W1973442967 crossrefType "journal-article" @default.
• W1973442967 hasAuthorship W1973442967A5023309852 @default.
• W1973442967 hasAuthorship W1973442967A5024592614 @default.
• W1973442967 hasAuthorship W1973442967A5027885433 @default.
• W1973442967 hasAuthorship W1973442967A5031442075 @default.
• W1973442967 hasAuthorship W1973442967A5041269947 @default.
• W1973442967 hasAuthorship W1973442967A5042584177 @default.
• W1973442967 hasAuthorship W1973442967A5060607144 @default.
• W1973442967 hasAuthorship W1973442967A5065674606 @default.
• W1973442967 hasAuthorship W1973442967A5087339700 @default.
• W1973442967 hasBestOaLocation W19734429672 @default.
• W1973442967 hasConcept C118552586 @default.
• W1973442967 hasConcept C126322002 @default.
• W1973442967 hasConcept C168563851 @default.
• W1973442967 hasConcept C170493617 @default.
• W1973442967 hasConcept C187212893 @default.
• W1973442967 hasConcept C2778140631 @default.
• W1973442967 hasConcept C2778949969 @default.
• W1973442967 hasConcept C2780687700 @default.
• W1973442967 hasConcept C2781063702 @default.
• W1973442967 hasConcept C42219234 @default.
• W1973442967 hasConcept C71924100 @default.
• W1973442967 hasConceptScore W1973442967C118552586 @default.
• W1973442967 hasConceptScore W1973442967C126322002 @default.
• W1973442967 hasConceptScore W1973442967C168563851 @default.
• W1973442967 hasConceptScore W1973442967C170493617 @default.
• W1973442967 hasConceptScore W1973442967C187212893 @default.
• W1973442967 hasConceptScore W1973442967C2778140631 @default.
• W1973442967 hasConceptScore W1973442967C2778949969 @default.
• W1973442967 hasConceptScore W1973442967C2780687700 @default.
• W1973442967 hasConceptScore W1973442967C2781063702 @default.

• next